Relationship Between the Clinical Pharmacist & Antibiotic Use by Using the Electronic Program

Electronic Medical Record Clinical Trial

Official title:

Relationship Between the Clinical Pharmacist & Antibiotic Use in Selected Infectious Disease Hospitals in El Beheira by Using the Electronic Program, Retrospective Cohort

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05002647
• Other study ID #: 14-2021/13
• Status: Not yet recruiting
• Start date: August 15, 2021
• Est. completion date: July 1, 2022

Study information

• Verified date: August 2021
• Source: Alexandria University
• Contact: Amira zidane
• Phone: 00201024585329
• Email: amira.zidan2yahoo[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A retrospective cohort study to explore the association between clinical pharmacists' interventions and antibiotic consumption through the use of the medical electronic reports and to identify mortality and cost savings in hospital infectious disease.

Description:

The role of clinical pharmacist includes :

1. a check of suitable selection and dosing of antimicrobials according to the diagnosis, type of infection, antimicrobial cultures as possible, comorbidities of patients (renal or hepatic function, etc), adverse effect, and drug interaction with other drugs.

2. Documentation of the clinical intervention, cost-saving, adverse effect,, antimicrobial culture and antimicrobial consumption on the electronic program (CPC "clinical patient care").

3. The clinical pharmacist inspector reviews the data recorded on CPC.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 3000
• Est. completion date: July 1, 2022
• Est. primary completion date: February 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All inpatient with infectious disease (disorders caused by organisms as (bacteria, viruses, fungi, or parasites).

Exclusion Criteria:

• Any other cause of hospital admission other than infectious disease.

Related Conditions & MeSH terms

• Clinical Pharmacists
• Electronic Medical Record

Intervention

Other:
• NO intervention
There is no intervention

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Alexandria University	Ministry of Health and Population, Egypt

References & Publications (3)

Dyar OJ, Huttner B, Schouten J, Pulcini C; ESGAP (ESCMID Study Group for Antimicrobial stewardshiP). What is antimicrobial stewardship? Clin Microbiol Infect. 2017 Nov;23(11):793-798. doi: 10.1016/j.cmi.2017.08.026. Epub 2017 Sep 4. Review. — View Citation

Karakonstantis S, Kalemaki D. Antimicrobial overuse and misuse in the community in Greece and link to antimicrobial resistance using methicillin-resistant S. aureus as an example. J Infect Public Health. 2019 Jul - Aug;12(4):460-464. doi: 10.1016/j.jiph.2019.03.017. Epub 2019 Apr 10. Review. — View Citation

Ourghanlian C, Lapidus N, Antignac M, Fernandez C, Dumartin C, Hindlet P. Pharmacists' role in antimicrobial stewardship and relationship with antibiotic consumption in hospitals: An observational multicentre study. J Glob Antimicrob Resist. 2020 Mar;20:131-134. doi: 10.1016/j.jgar.2019.07.009. Epub 2019 Jul 16. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antimicrobial consumption	consumption of antimicrobials (defined daily doses / 100 patient-days)	2 years
Primary	Days of therapy (DOT)	Number of days of each antimicrobial received for therapy	2 years
Primary	Length of therapy(LOT)	The number of days a patient takes an antibacterial drug, regardless of the number of different medications	2 years
Secondary	cost savings	(initial treatment cost × days before intervention) - (cost after intervention × days with this treatment),	2 years
Secondary	Mortality rate	in-hospital mortality rate (%)	2 years
Secondary	Antimicrobial resistance	resistance defined as resistance to at least one antimicrobial from the panel for all organisms, and for a subset of organisms belonging to the ESKAPE group (Enterococcus faecium, S. aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter spp.	2 years
Secondary	The incidence of adverse reaction of antimicrobial	An unexpected medical problem that happens during treatment with antimicrobial.	2 years